Avacta Group reports promising early results for Phase 1a study of AVA6000
Avacta Group plc (AIM: AVCT), a leading life sciences company dedicated to developing innovative oncology drugs and powerful diagnostics, has announced a crucial milestone in its drug development journey. The company has successfully dosed the third patient in the first cohort of the two-weekly Phase 1a dose escalation study of AVA6000. This peptide drug conjugate, […]